spacer
home > pmps > winter 2003 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

As PMPS passes its five year milestone may I welcome you to this Winter 2003 issue. So much has happened in the world of pharmaceutical manufacturing since the first issue in 1998, especially with the gathering pace of outsourcing. I'm delighted to be able to look back with a sense of pride at how much has been achieved, while looking forward to the next five years with anticipation. PMPS has kept in tune with developments as the market has steadily grown, with an increase in the number of contract manufacturing organisations (CMOs), business transactions and the number of employees working in the sector. The type of contract business has also diversified, with a trend towards an increase in the outsourcing of development activities needed to get products to market

faster. I say there has been a steady growth because it would be a gross exaggeration to suggest a growth rate of the market for development outsourcing of 25 per cent per year.

Figures of that magnitude, plucked out of thin air create unrealistic expectations and do little to enhance the reputation of this sector. For example, we have seen what happened with biotech when unfulfilled predictions turned sour. I'm conscious of a painful recession in biotech as sentiment plunged from the heady days of the market in 2000, driven as it was by so much hyperbole. Nevertheless, I remain optimistic about outsourcing as we look forward to the next Bio/PharMOS event with an exhibition and conference for manufacturing outsourcing services on 23rd-25th March 2004.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Editor of PMPS, Patricia Lobo rounds up current issues impacting on development and manufacturing in biotech and pharma.
spacer
Dr Patricia Lobo
spacer
spacer
spacer
Joanne Glover
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement